XBiotech Inc. discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. The company is a fully integrated biopharmaceutical developer with a state of the art research and manufacturing center on its 48 acre campus in Austin Texas. Its scientific focus includes antibodies that block interleukin 1 alpha for oncology, rheumatology, and neurology as well as an infectious disease pipeline targeting MRSA, C difficile, shingles, and influenza.…
XBiotech Inc. discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. The company is a fully integrated biopharmaceutical developer with a state of the art research and manufacturing center on its 48 acre campus in Austin Texas. Its scientific focus includes antibodies that block interleukin 1 alpha for oncology, rheumatology, and neurology as well as an infectious disease pipeline targeting MRSA, C difficile, shingles, and influenza. XBiotech’s True Human™ antibodies are derived from human donors who mount a natural immune response differentiating them from animal engineered therapeutics.
XBiotech generates revenue through product sales, licensing agreements, milestone payments, and contract services. In December 2019, the company sold its anti interleukin 1 alpha antibody Bermekimab for $750 million in cash and up to $600 million in potential milestone payments. Since 2020, XBiotech has returned $495 million to shareholders via stock repurchases and dividends. The company also earns revenue from a manufacturing supply agreement with a world leading pharmaceutical company, and from providing clinical trial operations services for that partner. These agreements, which ran from 2020 through 2023, have now concluded. Remaining cash supports ongoing operations and the advancement of its antibody pipeline.
XBiotech occupies a niche in the $247 billion global antibody market as the sole provider of True Human™ antibodies sourced directly from human donors. Most marketed antibodies are mouse derived and engineered, even those labeled as human, giving XBiotech a potential advantage in safety, efficacy, and development speed. The company competes with large biologics firms such as Amgen, Roche, and Pfizer, but differentiates itself through its proprietary discovery platform and integrated manufacturing capabilities. Its pipeline of IL 1 alpha inhibitors and anti infective antibodies addresses large unmet needs in oncology, autoimmune disorders, and infectious diseases.
XBiotech serves pharmaceutical companies, hospitals, and patients through its therapeutic programs and contract manufacturing services. Its manufacturing and clinical trial services have been provided to a world leading pharmaceutical company under a multi year supply agreement. The company’s antibody candidates are intended for use by healthcare providers treating cancer, rheumatoid arthritis, stroke, and infectious diseases. While specific customer names beyond the undisclosed partner are not disclosed, the broader base includes medical institutions and biopharma partners seeking novel antibody therapeutics.